Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · FENNEC PHARMACEUTICALS INC. (FENC)

Fennec Pharmaceuticals reports Phase 2 PEDMARK hearing-protection results in Japan

Positive Impact 3 of 5 other Written later

Fennec Pharmaceuticals said detailed results from the investigator-initiated Phase 2 STS-J01 study of PEDMARK in Japan met the primary endpoint, with hearing loss in 24.0% of patients versus a prespecified historical benchmark of 56.4%. The data were presented orally on September 17, 2026, at the 58th SIOP Annual Meeting, and the company said it is pursuing registration in Japan and exploring partnering or licensing options.

Key points

  • Primary endpoint met: ASHA-defined hearing loss in 24.0% (6 of 25) versus a prespecified historical benchmark of 56.4% (P=0.001)
  • 84.0% of patients had Grade 0 hearing loss by Brock criteria; no Grade 3 or Grade 4 hearing loss was observed
  • Objective tumor responses in 23 of 24 evaluable patients (95.8%)
  • Results presented at the 58th SIOP Annual Meeting in San Antonio, TX; Fennec is pursuing registration in Japan and exploring partnering or licensing for PEDMARK

The filing

CompanyFENNEC PHARMACEUTICALS INC. (FENC)
Form8-K, current report
Filed with the SECSep 17, 2026, 4:03 PM ET
Accession number0001104659-26-108565

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.